Aclarion, Inc. Faces Delisting Concerns
Ticker: ACONW · Form: 8-K · Filed: Aug 23, 2024 · CIK: 1635077
| Field | Detail |
|---|---|
| Company | Aclarion, INC. (ACONW) |
| Form Type | 8-K |
| Filed Date | Aug 23, 2024 |
| Risk Level | high |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $2,500,000, $1,642,177 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, regulatory-filing
Related Tickers: ACON
TL;DR
ACON might get delisted, stock could be in trouble.
AI Summary
Aclarion, Inc. filed an 8-K on August 23, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule. The company was formerly known as Nocimed, Inc. and was incorporated in Delaware.
Why It Matters
This filing indicates potential issues with Aclarion's continued listing on an exchange, which could impact its stock liquidity and investor confidence.
Risk Assessment
Risk Level: high — Delisting notices pose a significant risk to a company's stock value and operational continuity.
Key Numbers
- 001-41358 — SEC File Number (Identifies the company's filing history with the SEC.)
- 47-3324725 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Aclarion, Inc. (company) — Registrant
- Nocimed, Inc. (company) — Former company name
- August 23, 2024 (date) — Filing date
- August 22, 2024 (date) — Earliest event date
- Delaware (jurisdiction) — State of incorporation
FAQ
What specific listing rule or standard has Aclarion, Inc. failed to satisfy?
The filing does not specify the exact rule or standard that Aclarion, Inc. has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.
What is the immediate impact of this 8-K filing on Aclarion, Inc.'s stock trading?
This filing serves as a notification of potential delisting, which could lead to increased volatility and potential trading halts or suspension if the issue is not resolved.
Has Aclarion, Inc. provided any details on how it plans to address the delisting concerns?
The provided text of the 8-K filing does not contain information regarding Aclarion, Inc.'s plans to address the delisting concerns.
When was Aclarion, Inc. formerly known as Nocimed, Inc. and when did the name change occur?
The filing indicates that the former company name was Nocimed, Inc. and the date of the name change was February 26, 2015.
What is the business address and phone number for Aclarion, Inc. as listed in the filing?
The business address is 8181 Arista Place, Suite 100, Broomfield, Colorado 80021, and the business phone number is 833 275 2266.
Filing Stats: 649 words · 3 min read · ~2 pages · Grade level 14.4 · Accepted 2024-08-23 16:58:12
Key Financial Figures
- $2,500,000 — q Stock Market to maintain a minimum of $2,500,000 in stockholders' equity for continued l
- $1,642,177 — ompany reported stockholders' equity of $1,642,177, and, as a result, does not currently s
Filing Documents
- acon_8k.htm (8-K) — 31KB
- 0001683168-24-006005.txt ( ) — 246KB
- acon-20240822.xsd (EX-101.SCH) — 4KB
- acon-20240822_def.xml (EX-101.DEF) — 26KB
- acon-20240822_lab.xml (EX-101.LAB) — 36KB
- acon-20240822_pre.xml (EX-101.PRE) — 25KB
- acon_8k_htm.xml (XML) — 6KB
01 Notice of Delisting or Failure to
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Nasdaq Notice Regarding Stockholders' Equity Requirement On August 22, 2024, Aclarion, Inc. (the "Company") received a letter from The Nasdaq Stock Market LLC ("Nasdaq") indicating that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Stock Market to maintain a minimum of $2,500,000 in stockholders' equity for continued listing. In its annual report on Form 10-Q for the period ended June 30, 2024, the Company reported stockholders' equity of $1,642,177, and, as a result, does not currently satisfy Listing Rule 5550(b)(1). Nasdaq's letter has no immediate impact on the listing of the Company's common stock, which will continue to be listed and traded on Nasdaq, subject to the Company's compliance with the other continued listing requirements. Nasdaq's letter provides the Company has until August 29, 2024, to request an appeal of this determination, or the trading of the Company's common stock will be suspended at the opening of business on September 3, 2024. The hearing request would stay any suspension or delisting action pending the conclusion of the hearing process and the expiration of any additional extension period granted by the panel following the hearing. The Company intends to take all reasonable measures available to regain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq. The Company is currently evaluating its available options to resolve the deficiency and regain compliance with the Nasdaq minimum stockholders' equity requirement. The Company intends to request an appeal of this determination by the Nasdaq deadline. The Company's receipt of this letter from Nasdaq does not affect the Company's business, operations or reporting requirements with the Securities and Exchange Commission. 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ACLARION, INC. August 23, 2024 By: /s/ John Lorbiecki Name: John Lorbiecki Title: Chief Financial Officer 3